BioPharma Credit PLC Replacement: Dividend Declaration
RNS Number : 1708S
BioPharma Credit PLC
12 March 2021
The announcement released on 11 March 2021 at 5.15pm under
reference 0178S included an incorrect payment date in relation to
the interim dividend.
The correct payment date is 16 April 2021.
The corrected announcement is set out below.
BIOPHARMA CREDIT PLC
("BIOPHARMA CREDIT" OR THE "COMPANY")
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences
debt investor, is pleased to declare an interim dividend in respect
of the financial period ending 31 December 2020 of $0.02040119 per
ordinary share, payable on 16 April 2021 to ordinary shareholders
on the register as at 19 March 2021. The Company has chosen to
designate the entire amount of this interim dividend as an interest
distribution. Shareholders in receipt of such a dividend will be
treated for UK tax purposes as though they have received a payment
of interest. This will result in a reduction in the corporation tax
payable by the Company.
The $0.02040119 return comprises an ordinary dividend of $0.0175
and a special dividend of $0.00290119. As a result, total dividends
corresponding to the 2020 year totalled $0.07300119 per share.
The Company is currently paying and continues to target a 7 cent
annual dividend per ordinary share.
The default payment for dividends is in US dollars. However,
shareholders can elect to have dividends paid in sterling (GBP) and
the option to elect a sterling dividend payment for this dividend
will be available to shareholders until 19 March 2021 (the
Further details together with a copy of the Dividend Currency
Election Form, which should be sent to Link Group, 10(th) Floor,
Central Square, 29 Wellington Street, Leeds LS1 4DL when completed,
will be available on the Group's website shortly at
www.bpcruk.com/investor-materials. CREST shareholders must elect
Link Company Matters Limited
12 March 2021
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor
in debt from the life sciences industry and joined the LSE on 27
March 2017. The Company seeks to provide long-term shareholder
returns, principally in the form of sustainable income
distributions from exposure to the life sciences industry. The
Company seeks to achieve this objective primarily through
investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact email@example.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
March 12, 2021 12:00 ET (17:00 GMT)